Active Biotech AB (publ) (STO:ACTI)
Sweden · Delayed Price · Currency is SEK | Market Cap | 189.27M +88.6% |
| Revenue (ttm) | n/a |
| Net Income | -34.72M |
| EPS | -0.02 |
| Shares Out | 2.64B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,512,697 |
| Average Volume | 25,823,924 |
| Open | 0.0689 |
| Previous Close | 0.0718 |
| Day's Range | 0.0645 - 0.0719 |
| 52-Week Range | 0.0370 - 0.3400 |
| Beta | 1.33 |
| RSI | 56.40 |
| Earnings Date | May 7, 2026 |
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The compa... [Read more]
Financial Performance
Financial StatementsNews
Active Biotech AB Quarterly report: Q1 2026
Active Biotech AB has published its Q1 2026 quarterly earnings report on May 7, 2026.
Active Biotech AB Slides: Company presentation
Active Biotech AB has posted slides in relation to its latest quarterly earnings report, which was published on April 21, 2026.
Active Biotech AB Slides: Company presentation
Active Biotech AB has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.
Active Biotech AB Annual report: Q4 2025
Active Biotech AB has published its Q4 2025 annual report on February 12, 2026.
Active Biotech AB Quarterly report: Q4 2025
Active Biotech AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
Active Biotech AB: Active Biotech's patent related to a pharmaceutical formulation of tasquinimod will be granted in the US
Lund, November 25, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent and Trademark Office (USPTO) has issued a notification that the company's patent application rela...
Active Biotech AB Slides: Company Presentation
Active Biotech AB has posted slides in relation to its latest quarterly earnings report, which was published on November 6, 2025.
Active Biotech AB Quarterly report: Q3 2025
Active Biotech AB has published its Q3 2025 quarterly earnings report on November 6, 2025.
Active Biotech AB Quarterly report: Q2 2025
Active Biotech AB has published its Q2 2025 quarterly earnings report on August 21, 2025.
Active Biotech AB Quarterly report: Q1 2025
Active Biotech AB has published its Q1 2025 quarterly earnings report on May 8, 2025.
Active Biotech AB Annual report: Q4 2024
Active Biotech AB has published its Q4 2024 annual report on February 13, 2025.
Active Biotech AB Quarterly report: Q4 2024
Active Biotech AB has published its Q4 2024 quarterly earnings report on February 13, 2025.
Active Biotech AB Quarterly report: Q3 2024
Active Biotech AB has published its Q3 2024 quarterly earnings report on October 21, 2024.
Active Biotech AB Quarterly report: Q2 2024
Active Biotech AB has published its Q2 2024 quarterly earnings report on August 22, 2024.
Active Biotech AB Quarterly report: Q1 2024
Active Biotech AB has published its Q1 2024 quarterly earnings report on May 8, 2024.
Active Biotech AB Annual report: Q4 2023
Active Biotech AB has published its Q4 2023 annual report on February 8, 2024.
Active Biotech AB Quarterly report: Q4 2023
Active Biotech AB has published its Q4 2023 quarterly earnings report on February 8, 2024.
Active Biotech AB Transcript: Investor Update
Active Biotech AB Press release: Investor Update
Active Biotech AB issued a press release on December 1, 2023, disclosing material business information to investors.